{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:45:19Z","timestamp":1789202719084,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omtm.2024.101296","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T04:53:58Z","timestamp":1719896038000},"page":"101296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Subacute liver injury in two young infants following gene replacement therapy for spinal muscular atrophy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7038-0374","authenticated-orcid":false,"given":"Cassie","family":"Ables","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Lynne","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouied","family":"Alashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Book","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101296_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2024.101296_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, Incidence and Carrier Frequency of 5q-Linked Spinal Muscular Atrophy - A Literature Review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.omtm.2024.101296_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2024.101296_bib4","article-title":"Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtm.2024.101296_bib5","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.2147\/IJGM.S369021","article-title":"Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy","volume":"15","author":"Ramos-Platt","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.omtm.2024.101296_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101296_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2024.101296_bib9","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] - Onasemnogene Apoparvovec","year":"2020"},{"key":"10.1016\/j.omtm.2024.101296_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2024.101296_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.omtm.2024.101296_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2024.101296_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","article-title":"Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5\u00a0kg or Heavier in a Global Managed Access Program","volume":"132","author":"Chand","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2024.101296_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101296_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.omtm.2024.101296_bib17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/acn3.50855","article-title":"Abnormal fatty acid metabolism is a core component of spinal muscular atrophy","volume":"6","author":"Deguise","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2024.101296_bib18","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/MJT.0000000000000829","article-title":"Severe Acute Liver Injury Following Therapeutic Doses of Acetaminophen in a Patient With Spinal Muscular Atrophy","volume":"26","author":"Brehm","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.omtm.2024.101296_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101296_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s13023-021-02055-1","article-title":"Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies","volume":"16","author":"D\u2019Amico","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2024.101296_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101296_bib22","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101296_bib23","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jhep.2023.03.021","article-title":"Multidisciplinary approach and reactive immunosuppression for gene therapy-related hepatotoxicity","volume":"79","author":"Jagadisan","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2024.101296_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The Immunology of Macrophage Activation Syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101296_bib25","doi-asserted-by":"crossref","first-page":"e1532","DOI":"10.1093\/cid\/ciaa1277","article-title":"Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases","volume":"73","author":"Otto","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omtm.2024.101296_bib26","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2024.101296_bib27","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.omtm.2024.101296_bib28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.omtm.2024.101296_bib29","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2024.101296_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T17:55:43Z","timestamp":1733507743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2329050124001128"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101296","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subacute liver injury in two young infants following gene replacement therapy for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101296"}}